Cargando…

Prognostic significance of ras/p21 alterations in human ovarian cancer.

Ras/p21 oncoprotein expression and K-ras mutations were analysed by Western blot and/or K-ras oligonucleotide hybridization in 78 primary ovarian cancers, 20 omental metastases, two low malignant potential tumours (LMP), nine benign ovarian tumours and 10 normal ovaries. A cut-off value of an integr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scambia, G., Masciullo, V., Benedetti Panici, P., Marone, M., Ferrandina, G., Todaro, N., Bellacosa, A., Jain, S. K., Neri, G., Piffanelli, A., Mancuso, S.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1997
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223505/ https://www.ncbi.nlm.nih.gov/pubmed/9166952

Ejemplares similares

Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: correlation with histopathological features and epidermal growth factor receptors.
por: Scambia, G., et al.
Publicado: (1994)

hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer
por: Ercoli, A, et al.
Publicado: (1999)

Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome.
por: Ferrandina, G., et al.
Publicado: (1998)

Nm23 expression in endometrial and cervical cancer: inverse correlation with lymph node involvement and myometrial invasion.
por: Marone, M., et al.
Publicado: (1996)

Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma.
por: Maurizi, M., et al.
Publicado: (1996)

Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.
por: Scambia, G., et al.
Publicado: (1995)

Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis.
por: Ferrandina, G., et al.
Publicado: (1997)

Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines
por: Ferlini, C, et al.
Publicado: (1999)

Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer.
por: Scambia, G., et al.
Publicado: (1995)

p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer
por: Ferrandina, G, et al.
Publicado: (1999)

Cathepsin D and epidermal growth factor in human breast cyst fluid.
por: Scambia, G., et al.
Publicado: (1991)

Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone and epidermal growth factor.
por: Scambia, G., et al.
Publicado: (1991)

Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells.
por: Scambia, G., et al.
Publicado: (1990)

Prognostic significance of methyl-p-hydroxy-phenyllactate-esterase activity in laryngeal squamous cell carcinoma.
por: Maurizi, M., et al.
Publicado: (1998)

Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer
por: D'Agostino, G, et al.
Publicado: (2003)

Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies.
por: Scambia, G., et al.
Publicado: (1990)

Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
por: Ferrandina, Gabriella, et al.
Publicado: (2014)

Lethal Clostridium difficile Colitis Associated with Paclitaxel and Carboplatin Chemotherapy in Ovarian Carcinoma: Case Report and Review of the Literature
por: Masciullo, V., et al.
Publicado: (2010)

Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients
por: Ferrandina, G, et al.
Publicado: (2008)

Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis.
por: Ferlini, C., et al.
Publicado: (1997)

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence
por: Mascilini, Floriana, et al.
Publicado: (2014)

25P The impact of COVID-19 on delaying diagnostic-therapeutic pathways of endometrial cancer patients: The Italian real-world scenario
por: Di Donato, V., et al.
Publicado: (2022)

High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.
por: Benedetti Panici, P., et al.
Publicado: (1997)

Environmental Contaminants Exposure and Preterm Birth: A Systematic Review
por: Porpora, Maria Grazia, et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters
por: Ferrandina, G, et al.
Publicado: (2005)

Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial
por: Ferrandina, G, et al.
Publicado: (2009)

CD133 antigen expression in ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2009)

Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome
por: Legge, Francesco, et al.
Publicado: (2008)

In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.
por: Pierelli, L., et al.
Publicado: (1998)

Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia
por: Kaburagi, Taeko, et al.
Publicado: (2021)

Nuclear Expression of β-Catenin Is Associated with Improved Outcomes in Endometrial Cancer
por: Masciullo, Valeria, et al.
Publicado: (2022)

Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients
por: Legge, Francesco, et al.
Publicado: (2011)

Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial
por: Dell’ Anna, T, et al.
Publicado: (2012)

First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
por: Marchetti, Claudia, et al.
Publicado: (2019)

Adrenomedullin in Ovarian Cancer: Foe In Vitro and Friend In Vivo?
por: Baranello, Cinzia, et al.
Publicado: (2012)

MiR-200c and HuR in ovarian cancer
por: Prislei, Silvia, et al.
Publicado: (2013)

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
por: Lorusso, D, et al.
Publicado: (2012)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Is CA72-4 a Useful Biomarker in Differential Diagnosis between Ovarian Endometrioma and Epithelial Ovarian Cancer?
por: Anastasi, Emanuela, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d1v0vp9qlgtp0e8i126pfs84m0